2009
DOI: 10.1186/1756-3305-2-18
|View full text |Cite
|
Sign up to set email alerts
|

Nitric oxide production by Biomphalaria glabrata haemocytes: effects of Schistosoma mansoni ESPs and regulation through the extracellular signal-regulated kinase pathway

Abstract: Background: Schistosoma mansoni uses Biomphalaria glabrata as an intermediate host during its complex life cycle. In the snail, the parasite initially transforms from a miracidium into a mother sporocyst and during this process excretory-secretory products (ESPs) are released. Nitric oxide (NO) and its reactive intermediates play an important role in host defence responses against pathogens. This study therefore aimed to determine the effects of S. mansoni ESPs on NO production in defence cells (haemocytes) fr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
32
0

Year Published

2010
2010
2023
2023

Publication Types

Select...
3
3

Relationship

1
5

Authors

Journals

citations
Cited by 36 publications
(35 citation statements)
references
References 43 publications
2
32
0
Order By: Relevance
“…In some experiments, the proteasome inhibitor Z-Leu-Leu-Leu-aldehyde (MG132; 50 μM; Merck Chemicals, Nottinghamshire, UK), the MEK1/2 inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126; 1-10 μM; Sigma), or vehicle control (0.1% (v/v) DMSO; Sigma) were added with or without ESPs. The inhibitor, U0126, has previously been used at these concentrations to block MEK1/2 activity in B. glabrata and Lymnaea stagnalis haemocytes, subsequently suppressing the phosphorylation (activation) of ERK (Plows et al 2004;Plows et al 2005;Wright et al 2006;Zahoor et al 2008Zahoor et al , 2009). The concentration chosen for MG132 was similar to that used by Kim et al (1999).…”
Section: Haemocytes and Haemocyte Treatmentsmentioning
confidence: 99%
See 4 more Smart Citations
“…In some experiments, the proteasome inhibitor Z-Leu-Leu-Leu-aldehyde (MG132; 50 μM; Merck Chemicals, Nottinghamshire, UK), the MEK1/2 inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126; 1-10 μM; Sigma), or vehicle control (0.1% (v/v) DMSO; Sigma) were added with or without ESPs. The inhibitor, U0126, has previously been used at these concentrations to block MEK1/2 activity in B. glabrata and Lymnaea stagnalis haemocytes, subsequently suppressing the phosphorylation (activation) of ERK (Plows et al 2004;Plows et al 2005;Wright et al 2006;Zahoor et al 2008Zahoor et al , 2009). The concentration chosen for MG132 was similar to that used by Kim et al (1999).…”
Section: Haemocytes and Haemocyte Treatmentsmentioning
confidence: 99%
“…After 30 min at room temperature (RT), the adherent haemocytes that formed the cell monolayer were washed twice with CBBS and then challenged for 1 h with S. mansoni ESPs. The ESP concentrations chosen (0-20 μg/ml in CBSS) were those employed in our previous studies (Zahoor et al 2008(Zahoor et al , 2009). In some experiments, the proteasome inhibitor Z-Leu-Leu-Leu-aldehyde (MG132; 50 μM; Merck Chemicals, Nottinghamshire, UK), the MEK1/2 inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126; 1-10 μM; Sigma), or vehicle control (0.1% (v/v) DMSO; Sigma) were added with or without ESPs.…”
Section: Haemocytes and Haemocyte Treatmentsmentioning
confidence: 99%
See 3 more Smart Citations